Dr. Leonard P.Guarente,Ph.D.
Novartis Professor of Biology
Massachusetts Institute of Technology,Cambridge, USA
Studies of Dysferlin in Muscle Repair
November 20th (Friday) 10:30am-11:30am JST
(November 19th, Thursday, 8:30pm-9:30pm, US East Standard Time)
Dr. Leonard P. Guarente is the Novartis Professor of Biology at MIT, Director of the Glenn Labs for the Science of Aging at MIT, and affiliate of the Koch Institute for Integrative Cancer Research. His initial work was in the area of transcription, and his lab identified UASs, TATA-binding protein, and transcriptional coactivators. His lab went on to discover that a yeast protein SIR2 was a key anti-aging factor in that organism and that a SIR2-related proteins, termed sirtuins, slow the aging process in a wide variety or organisms ranging up to mammals. Moreover his lab discovered the novel biochemical activity for yeast and human sirtuins Sir2 and SIRT1 — NAD-dependent deacetylation. The identification of the biochemical activity of sirtuins also provided an assay for screening for drugs that can activate SIRT1. In addition, it has emerged that NAD+ levels decline in an aging population, and the use of NAD+ precursors offers a promising treatment to restore NAD levels, sirtuin activity and health benefits to an aging population. His current research includes the pathophysiology and treatments of ALS; treatments for muscular dystrophy; and genes and pathways that determine the rate of aging of the human brain.
He was elected to American Academy of Arts and Science in 2004 and the French Academie des Sciences in 2009. He is the recipient of the Feodor Lynen Award, Miami Winter Symposium in 2012, the Dart/NYU Biotechnology Achievement Award in 2009, and the Irving Wright Award of the American Federation of Aging Research in 2014. He is author of Ageless Quest and an editorial board member of Cell, Cell Metabolism, EMBO Reports, TIG, Aging, and Experimental Gerontology. He is a founder of Elysium Health and Galelei Biosciences.
Dr. Brian Kennedy, Ph.D.
Departments of Biochemistry and Physiology
Director, Centre for Healthy Ageing
National University of Singapore, Singapore
November 20th (Friday) 2:00pm-3:00pm JST
(November 20th, Friday, 1:00pm-2:00pm, Singapore Time)
Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of delaying, detecting, and preventing human aging and associated diseases. He is a Professor in the Departments of Biochemistry and Physiology at National University Singapore and Director of the Centre for Healthy Ageing in the National University Health System. From 2010 to 2016 he was the President and CEO of the Buck Institute for Research on Aging. Currently he remains as a Professor at the Institute. Dr. Kennedy also has an adjunct appointment at the USC Davis School of Gerontology. Dr. Kennedy is also actively involved Biotechnology companies, serving in consulting and Board capacities, as well as Scientific Director of Affirmativ Health. Dr. Kennedy also serves as a Co-Editor-In-Chief at Aging Cell.
Dr. Jing-Dong “Jackie” Han, Ph.D.
Peking-Tsinghua Center for Life Sciences
Academy for Advanced Interdisciplinary Studies
Peking University, Beijing, China
Heterogeneity of Aging in Human Populations
November 20th (Friday) 3:30pm-4:30pm JST
(November 20th, Friday, 2:30pm-3:30pm, Beijing Time)
Prof. Jing-Dong Jackie Han obtained Ph.D. degree from Albert Einstein College of Medicine. She had her postdoctoral training at The Rockefeller University and Dana-Farber Cancer Institute. In 2004, she became an investigator/professor at the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. She is currently a director of the CAS-Max Planck Partner Institute for Computational Biology. In 2019, she became a tenured professor at Peking University. Her research focuses on the structure and dynamic inference of molecular networks，using a combination of large-scale experiments and computational analysis to explore the design principles of the networks and to find how the complex phenotypes, such as aging, cancer and stem cell development are regulated through molecular networks. She was awarded the Chinese Academy Sciences Hundred Talent Plan and NSFC Outstanding Young Scientist Award in 2006, and the Hundred Talent Plan Outstanding Achievement Award in 2009, selected as a Max Planck Follow in 2011 and a MaxNetAging Fellow in 2014, F1000 faculty in developmental biology in 2016.
1.Systems biology of development and aging
2.Evolution of regulatory networks
3.Computational algorithm development for data integration and network analysis
Dr. Linda Partridge, D.Phil.
Max Planck Institute for Biology of Ageing
Biological Secretary and Vice-President
TheRoyal Society, London, UK
November 20th (Friday) 5:00pm-6:00pm JST
(November 20th, Friday, 9:00am-10:00am, Central European Time)
Linda Partridge works on the biology of ageing. Her research is directed to understanding the mechanisms by which healthy lifespan can be extended in laboratory model organisms and humans. Her work has focussed in particular on the role of nutrient-sensing pathways and diet, and her primary interest is in geroprotective drugs. She is the recipient of numerous awards, was honoured with a DBE for Services to Science in 2009 and is a Fellow of the Royal Society. She is the founding director of the Max Planck Institute for Biology of Ageing and Biological Secretary elect at the Royal Society.
Dr. Cynthia Kenyon, Ph.D.
Vice President, Aging Research, Calico, San Francisco, Calinornia, USA
Proteostasis in the immortal C. elegans germ lineage
November 21st (Saturday) 10:30am-11:30am JST
(November 20th, Friday, 5:30pm-6:30pm, US Pacific Standard Time)
Cynthia Kenyon helped to pioneer the genetic analysis of aging, showing that the aging process is plastic and subject to regulation. Her work with long-lived mutant roundworms stimulated an intensive study of the molecular regulation of aging, and led to the realization that a conserved endocrine network regulates the aging process throughout the animal kingdom. Dr. Kenyon was on the UCSF faculty for many years, and is currently Vice President of Aging Research at Calico Life Sciences, LLC.
Dr. Tamotsu Yoshimori, Ph.D.
Distinguished Professor of Osaka University
Department of Genetics
Graduate School of Medicine
Osaka University, Osaka, Japan
The Intracellular Self-Degradation System
Fighting against Diseases and Aging
November 21st (Saturday) 2:00pm-3:00pm JST
Prof. Tamotsu Yoshimori was graduated from the Department of Biology, Faculty of Science, Osaka University and studied at the Graduate School of Medicine at Osaka University. He received his PhD degree in Medical Science from Osaka University. After working at several places including European Molecular Biology Laboratory (Prof Kai Simons’ lab) and National Institute of Basic Biology (Prof Yoshinori Ohsumi’s lab), he is now a distinguished professor of Osaka University (Graduate School of Medicine and of Frontier Biosciences), a Dean of Graduate School of Frontier Biosciences and a director of Research Center for Autophagy, Osaka University. His research interests are focused on intracellular membrane trafficking, and especially for the last 23 years, autophagy. He started his study on mammalian autophagy in the lab of Prof Yoshinori Ohsumi, a founder of the field who received Nobel Prize in Physiology or Medicine in 2016. Yoshimori identified LC3 as an autophagosome-binding protein, which has been widely used as the gold standard in autophagy assays. The paper has been cited over 5,000 times. He also provided new insights into membrane biogenesis in autophagy and the role of autophagy in pathogen defense and suppression of various diseases. He authored or coauthored over 220 journal articles and book chapters. He is an editor of Journal Cell Science, and on the editorial board of Journal of Cell Biology, and so on. He was a president of Japan Society for Cell Biology (2016-2018). He was awarded the Prize for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology in 2013, the Kakiuchi Saburo Memorial Prize by the Japanese Biochemical Society in 2014, Highly Cited Researcher 2014 and 2015 by Thomson Reuters, the Uehara prize in 2016 by the Uehara Memorial Foundation, the Mochida Memorial Academic Prize in 2017, Highly Cited Researcher 2019 by Web of Science, and Medal with Purple Ribbon 2019.
Dr. Eiji Hara, Ph.D.
Department of Molecular Microbiology
Research Institute for Microbial Diseases
Osaka University, Osaka, Japan
Cellular senescence in aging and cancer
November 21st (Saturday) 3:30pm-4:30pm JST
Eiji Hara obtained his Ph.D. at the Tokyo University of Science in 1993 and moved to the Lawrence Berkeley Laboratory, University of California (Berkeley, USA) as a Postdoctoral Fellow to work with Dr. Judith Campisi on cellular senescence. In 1995, he joined the Imperial Cancer Research Fund laboratories (London, UK) as a Postdoctoral Fellow to work with Dr. Gordon Peters on cell cycle control, and then became a Group Leader at the Cancer Research UK-Paterson Institute for Cancer Research (Manchester, UK) in 1998. In 2003, he returned to Japan as a Professor at the University of Tokushima (Tokushima, Japan) and moved to the Japanese Foundation for Cancer Research (Tokyo, Japan) as a Division Chief in 2008. In 2015, he moved to Osaka University (Osaka, Japan) as a Professor. He currently heads the center for studies on mechanisms and regulation of aging, a project supported by Japan Agency for Medical Research and Development (AMED). His work focused on the mechanisms of cellular senescence and discovered that p16INK4a is a key inducer of cellular senescence. He is currently studying the roles of cellular senescence in aging and aging-associated diseases.
Dr. Adam Antebi, Ph.D.
Max Planck Institute for Biology of Ageing
Small nucleoli are a cellular hallmark of longevity
November 21st (Saturday) 5:00pm-6:00pm JST
(November 21st, Saturday, 9:00am-10:00am, Central European Time)
Adam Antebi is one of the founding Directors of the Max Planck Institute for Biology of Ageing, Cologne, Germany and an Editor-in-Chief at the journal Aging Cell. He has devoted his research over the last twenty years to unraveling regulatory mechanisms governing animal longevity. During this time, he discovered that steroid hormone signaling and components of developmental clocks regulate animal life span and that the nucleolus is a key convergence point of regulation for dietary restriction and other longevity pathways. He is the recipient of the Paul Glenn/American Federation for Aging Research Breakthrough in Gerontology Award, the Ellison Medical Foundation Senior Scholar in Aging Award, the ADPS Longevity Award, the European Research Council Advanced Grant, and is a member of EMBO.
Dr. Thomas Rando, M.D., Ph.D.
Department of Neurology and Neurological Sciences
Director, The Glenn Center for the Biology of Aging
Stanford University School of Medicine, Stanford, California, USA
Aging and Rejuvenation of Stem Cells
November 22nd (Sunday) 10:30am-11:30am JST
(November 21st, Saturday, 5:30pm-6:30pm, US Pacific Standard Time)
Thomas Rando received his AB, MD, and PhD degrees from Harvard University and then completed a residency in neurology at UCSF and postdoctoral training at Stanford University. He is currently Professor of Neurology and Neurological Sciences and Director of the Glenn Center for the Biology of Aging at Stanford University School of Medicine. Dr. Rando directs the Center for Tissue Regeneration, Repair, and Restoration (CTR3), a program in regenerative medicine combining expertise in stem cell biology and bioengineering, at the VA Palo Alto Health Care System where he is also Chief of Neurology.
Dr. Rando’s research focuses on stem cell biology, with particular interest in stem cell aging. He has pioneered the field of systemic factors as regulators of cellular aging based upon seminal studies done in his laboratory using the technique of heterochronic parabiosis. These studies have formed the foundation of current approaches to epigenetic rejuvenation. His laboratory has also pioneered studies of the regulation of stem cell quiescence, with a focus both on the basic biology and therapeutic applications. Dr. Rando has received numerous awards including the NIH Director’s Pioneer Award, an NIH MERIT Award, the “Breakthroughs in Gerontology” Award from the American Federation for Aging Research, and a Transformative Research Award from the NIH. Dr. Rando is a member of the National Academy of Medicine and a Fellow of the American Association for the Advancement of Science. He is a Visiting Fellow at the Institute for Advanced Study at the Hong Kong University of Science and Technology and he holds honorary professorships from the Chinese Academy of Medical Science and from Aarhus University in Denmark. Dr. Rando is a scientific founder of Fountain Therapeutics and serves on the Board of Directors of the American Federation for Aging Research.
Dr.Shin-ichiro Imai, M.D., Ph.D.
Department of Developmental Biology
Department of Medicine (joint)
Washington University School of Medicine, St. Louis, Missouri, USA
Achieving Productive Aging:
The Systemic Regulatory Mechanism of
Mammalian Aging and Longevity and Anti-Aging Intervention
November 22nd (Sunday) 12:00pm-1:00pm JST
Shin-ichiro Imai received his MD and PhD degrees in 1989 and 1995, respectively, from Keio University School of Medicine in Tokyo, Japan, where he studied cellular aging-associated transcriptional regulation in human fibroblasts and proposed his “Heterochromatin Island Hypothesis of Aging.” In 1997, he moved to the US and joined the laboratory of Leonard Guarente at the Massachusetts Institute of Technology as a Human Frontier Science Program Long-Term Fellow. There, he made a paradigm-shifting discovery of the NAD+-dependent protein deacetylase activity of yeast and mammalian Sir2 proteins and published his landmark paper in the journal Nature in 2000. In 2001, he joined the faculty of Washington University School of Medicine in St. Louis, Missouri, and is currently Professor in the Departments of Developmental Biology and Medicine. Professor Imai’s laboratory has been studying the roles of mammalian sirtuins and NAMPT-mediated NAD+ biosynthesis in the systemic regulation of aging and longevity in mammals. Based on his research, he has proposed a novel concept of a systemic regulatory network for mammalian aging/longevity control, named the “NAD World.”
His long-term goal is to achieve “productive aging,” which aims to make our later lives as healthy and productive as possible, by understanding the spatial and temporal dynamics of our physiological system and developing nutraceutical/pharmaceutical anti-aging interventions. Since 2017, Professor Imai has also been serving as the Invited Chief Scientist and leading a research group in the Institute for Biomedical Research and Innovation in Kobe, Japan. He has received many prestigious awards for his works, including the American Society for Cell Biology/Glenn Foundation Award, the Ellison Medical Foundation New Scholar Award in Aging, the American Diabetes Association Innovation Award, the Juvenile Diabetes Research Foundation Innovation Award, the Glenn Award for Research in Biological Mechanisms of Aging, the WUSM 2008 Distinguished Investigator Award, the Ellison Medical Foundation Senior Scholar in Aging Award, Glenn/AFAR Breakthroughs in Gerontology (BIG) Award, and International Okamoto Award. He was also selected as one of “The Most Influential 100 people for Japan 2017” by Nikkei Business. He is living with his wife in the suburb of St. Louis and enjoying his Midwest life.
Dr. Masashi Yanagisawa, M.D., Ph.D.
Professor and Director
International Institute for Integrative Sleep Medicine, The University of Tsukuba,
Toward the Mysteries of Sleep
November 22nd (Sunday) 2:00pm-3:00pm JST
In 1988, as a graduate student at University of Tsukuba, Yanagisawa discovered endothelin, a potent vasoconstrictor peptide from vascular endothelial cells, which sparked an intense research activity in the field. In the subsequent year, his group identified a G protein-coupled receptor for endothelin, which would become an important drug target; the endothelin receptor antagonist bosentan was approved in 2001 for the treatment of pulmonary hypertension. After moving to University of Texas Southwestern Medical Center in 1991 as a young HHMI Investigator, he identified the endothelin-converting enzyme, a metalloprotease that generate the active, mature endothelin peptides. Through gene-targeting experiments in mice, he also discovered in 1994 that the endothelin pathway is essential for embryonic development of certain neural crest derived tissues, and that endothelin-B receptor deficiency causes Hirschsprung disease in mice and humans. In 1996, he initiated a systematic search for endogenous ligands of “orphan” G protein-coupled receptors, which resulted in his 1998 discovery of orexin, a hypothalamic neuropeptide. He then discovered in 1999 that orexin deficiency causes the sleep disorder narcolepsy. This opened up a new avenue in sleep research, and led to a better understanding of sleep/wake switching mechanisms in the brain. The notion that orexin is an important endogenous waking agent led to the development of orexin receptor antagonists as sleep-inducing drug, first of which, suvorexant, was approved in 2014. Recognizing, however, that the fundamental mechanism for sleep homeostasis still remains a mystery, in 2010 he embarked upon a highly ambitious project of polysomnography (EEG/EMG)-based forward genetic screen for sleep/wake abnormalities in chemically mutagenized mouse cohort. This large-scale project is now continuing in Tsukuba, Japan, and has recently led to identification of several new genes that are importantly involved in the regulation of sleep amounts and the level of sleep need. Since one of these mutant strains, Sleepy, carried a gain-of-function allele in the serine/threonine kinase Sik3, Yanagisawa systematically compared the phospho-proteomic states of Sleepy and sleep-deprived mouse brains in collaboration with Qinghua Liu. This effort has led to the hypothesis that cumulative phosphorylation and dephosphorylation of a specific subset of mostly synaptic proteins may underlie accumulation and dissipation of sleep need, thus representing the mysterious molecular substrate for “sleepiness.”